Understanding how our immune cells fight tuberculosis
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
This research aims to understand how specific immune cells in people respond to different parts of the tuberculosis germ to better protect us from the disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11113853 on NIH RePORTER |
What this research studies
Our immune system's CD4 T cells are crucial for fighting tuberculosis (TB), but we don't fully understand which parts of the TB germ these cells target to provide protection. We've found that some parts of the TB germ that T cells usually recognize are very stable, while we've also discovered new, 'rare variable antigens' that change over time. This suggests that our immune system's response to these changing antigens might be more effective at harming the TB germ. By studying these different responses in people, we hope to uncover the secrets to stronger immunity against TB.
Who could benefit from this research
Good fit: This research focuses on understanding immune responses in adults, particularly those who have been exposed to tuberculosis.
Not a fit: Patients who do not have tuberculosis or a history of exposure to it may not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to better vaccines or treatments for tuberculosis by identifying the most effective targets for our immune system.
How similar studies have performed: While the idea of immune recognition providing protection is established, the discovery of 'rare variable antigens' and their potential role in TB immunity represents a novel approach.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Ernst, Joel D. — University of California, San Francisco
- Study coordinator: Ernst, Joel D.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.